Important Safety Warnings for Selpercatinib

Important Safety Warnings for Selpercatinib

Using Selpercatinib may cause multiple serious side effects requiring vigilance from both patients and doctors. First, liver problems, manifested as elevated liver enzymes, which can sometimes be severe. Patients should inform their doctor immediately if they experience yellowing of the skin or whites of the eyes, tea-colored urine, drowsiness, loss of appetite, or right upper abdominal pain. Second, lung problems, potentially severe or even life-threatening lung inflammation, leading to shortness of breath, cough, or fever. Additionally, high blood pressure is common and can be serious; blood pressure should be monitored regularly during treatment. Regarding the heart, Selpercatinib may cause slow, fast, or irregular heartbeat (QT prolongation), requiring periodic ECGs and electrolyte checks.

Common Side Effects of Selpercatinib

In adult patients with solid tumors, the most common side effects of Selpercatinib include swelling (edema) in the arms, legs, hands, or feet, diarrhea, fatigue, dry mouth, abdominal pain, constipation, rash, nausea, and headache. In pediatric patients aged 2 years and older, common side effects also include musculoskeletal pain, bleeding, fever, vomiting, cough, coronavirus infection, and upper respiratory tract infection. Regarding laboratory findings, both adults and children may experience decreased white blood cell counts, elevated liver enzymes, decreased blood calcium or sodium, and other abnormalities. Most of these side effects are mild to moderate and can be managed with symptomatic treatment or dose adjustment.

Other Serious Adverse Reactions and Precautions for Selpercatinib

Selpercatinib may also cause bleeding problems, including vomiting blood, blood in urine, black stools, coughing up blood, unusual bruising, etc., which can be fatal in severe cases. Allergic reactions (fever, rash, muscle and joint pain) are common, especially during the first month of treatment. Tumor lysis syndrome may occur due to rapid breakdown of cancer cells, presenting with nausea, vomiting, muscle weakness, edema, seizures, etc., requiring emergency management. Furthermore, Selpercatinib may affect wound healing; it should be stopped at least 7 days before planned surgery. It may also cause hypothyroidism, requiring monitoring of thyroid hormone levels. Pediatric patients should be alert for hip slippage. Fertility in women and men may be affected, and the drug is harmful to the fetus. Effective contraception must be used during treatment and for 1 week after stopping the drug.